AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01929603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin (CYP inducer) 600mg taken once daily from Day 5 to Day 14 (Part A)
Study NCT01929603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib tablet dosing
Description: Olaparib 300mg tablet taken on Days 1 and 14 (Part A). Part B dosing is 300mg olaparib bi-daily
Study NCT02202577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine - Isopropyl alcohol
Description: Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
Study NCT02202577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine Scrub and Paint
Description: Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
Study NCT02943460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match cilofexor
Description: Tablet(s) administered orally once daily with food
Study NCT02943460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match cilofexor
Description: Tablet(s) administered orally once daily with food
Study NCT04537039 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Frailty screening for people over 65 living at home.
Description: The home care services will carry out the SEGA-A test.
Study NCT04294667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZP
Description: Subjects will receive dapirolizumab pegol at prespecified time-points.
Study NCT04294667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo at prespecified time-points.
Study NCT00953381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg ilaprazole
Description: One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
Study NCT00953381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg ilaprazole
Description: Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
Study NCT00953381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg ilaprazole
Description: Four 5-mg ilaprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
Study NCT00953381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mg omeprazole
Description: One 20-mg omeprazole capsule (AstraZeneca, Losec) together with four placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
Study NCT00661973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: inhaled budesonide (turbohaler) 400 micrograms twice a day for 4 weeks
Study NCT03578757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 21-day residential program
Description: Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders (and a negative energy balance of 500 kcal/day), physical activity (2h30 per day, minimum), thermal spa treatment (2h per day, minimum), and health education (1h30 per day, minimum: cooking, nutrition and physical activity classes...). Physical activity will be diverse (endurance, strength, circuit training) and personalized to the target of each participant.~The intervention group will benefit from psychological interventions based on validated approaches of stress (3 x 1h30 per week). Participants will attend psychological sessions by group of less than 10 individuals. Individual meeting with the psychologist will occur at least twice: at the beginning of the residential program and at the end.~After the spa residential program, participants will undergo a one-year at-home follow-up.
Study NCT03578757 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 21-day residential program
Description: Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders (and a negative energy balance of 500 kcal/day), physical activity (2h30 per day, minimum), thermal spa treatment (2h per day, minimum), and health education (1h30 per day, minimum: cooking, nutrition and physical activity classes...). Physical activity will be diverse (endurance, strength, circuit training) and personalized to the target of each participant.~The intervention group will benefit from psychological interventions based on validated approaches of stress (3 x 1h30 per week). Participants will attend psychological sessions by group of less than 10 individuals. Individual meeting with the psychologist will occur at least twice: at the beginning of the residential program and at the end.~After the spa residential program, participants will undergo a one-year at-home follow-up.
Study NCT00096083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isolated perfusion
Study NCT00096083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan
Study NCT02291536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetrahydrocannabinol
Study NCT02291536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol
Study NCT02291536 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00470847 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lapatinib
Description: Orally twice daily
Study NCT00470847 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Whole Brain Radiation
Description: 15 treatments over a period of 3 weeks
Study NCT00470847 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Herceptin
Description: Herceptin 4mg/kg loading dose then 2 mg/kg IV once weekly, then once every three weeks after cycle 3.
Study NCT03456440 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI scan of the patients liver with DWI and acquisition of ADC value.
Study NCT01986140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAXMAN Orbis Scalp Cooler
Description: Treatment with Orbis scalp cooling cap
Study NCT01986140 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control No treatment
Description: No treatment to prevent hair loss
Study NCT02519556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet, once a day for 6 months. Dilute one sachet in 100ml of water and take it in every morning.
Study NCT02116387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: Patients randomized to this arm will participate in a classic physical therapy program (15 weeks, a total of 15 sessions).
Study NCT02116387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-Moove Physical Therapy
Description: Patients randomized to this arm will participate in a physical therapy program using the I-Moove device (15 weeks, a total of 15 sessions).
Study NCT03985579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiology taping application
Description: Application of elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability from athletic injuries and a variety of other physical disorders
Study NCT04338529 — intervention group
Intervention type: DRUG
Intervention: Binosto 70Mg Effervescent Tablet
Description: As discussed in group descriptions
Study NCT05129800 — intervention group
Intervention type: OTHER
Intervention: Platelet-rich plasma
Description: PRP preparation involved, withdrawal 8-10ml from each patient into a tube containg either 3,8 % sodium citrate and either enoxaparin gel or thixotropic cell-separation gel. The tubes were centrifuged at either 3900 rpm for 10 minutes or at 1500g for 5 minutes, resulting in four layers: a cell-rich layer at the bottom of the tube covered by the separating gel, a PRP layer on top of the gel, and a platelet-poor plasma (PPP) layer at the top. The tube was gently agitated in order to mix the PPP with the PRP. The solution, cca 4-5ml, was withdrawn with a needle and injected to the scalp-frontoparietal region using either a syringe and a 4mm needle or an injector. According to the protocol of our hospital, the injections to the scalp were spaced 0.5-1cm apart.~PRP was applied once every month for 3 months. Macroscopic and digital phototrichographic photos were taken before the beginning of treatment, 1 month after the last injection, and 3 months after the end of treatmert.
Study NCT05129800 — intervention group
Intervention type: OTHER
Intervention: Mesotherapy
Description: For mesotherapy, usually around 5ml of saline solution was withdrawn using a needle and released to the selected ampule containing adipose tissue stem-cell conditioned media and mixture of recombinant growth factors, in a powder form. We used preparations from two different companies, differing in the combination and concentration of ingredients. After the injection of normal saline, the ampule was gently agitated in order to disperse the powder and injected to the scalp-frontoparietal region using either a syringe and a 4mm needle or a gun injector. The injections were spaced 0.5-1cm apart.~Mesotherapy was repeated every 1-2 weeks for 6-7 times according to the protocol recommended for each preparation. Macroscopic and phototrichographic photos were taken before the beginning of treatment, a month after the last injection and 3 months after the end of treatment.
Study NCT01723774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD0332991
Study NCT01723774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Study NCT01723774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Study NCT01723774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (standard of care)
Description: -Breast and axillary lymph node surgery
Study NCT02105701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg capsule
Study NCT02172053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compensatory Workplace Exercise (CWE) - Comparative Group
Description: The comparative group will receive warming up and stretching and light resisted exercise with elastic bands. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up for 5 minutes and 15 minutes of the specific training . The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
Study NCT02172053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual Resistance Exercise (IRE) - Intervention Group
Description: Intervention group will receive warming up and stretching, and a specific resistance training with increase progress load. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up and stretching for 5 minutes and 15 minutes of the specific training. The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
Study NCT02314234 — intervention group
Intervention type: DRUG
Intervention: sugammadex (Bridion)
Description: single dose of sugammadex at skin incision
Study NCT03576222 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICO DRESSING
Description: USE PICO DRESSING ON SURGICAL INCISION AFTER ABDOMINAL WALL REPAIR IN THE SURGICAL ROOM
Study NCT03576222 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MEPORE dressing
Description: MEPORE dressing
Study NCT02830841 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham RIPC
Description: Only blood pressure cuff will be placed to the patient, but no inflation or deflation will be performed.
Study NCT02350673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab IV infusion at doses of 800 mg q2w or 1200 mg q3w.
Study NCT02350673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cergutuzumab Amunaleukin
Description: Participants will receive cergutuzumab amunaleukin IV infusion at escalated doses and at different dosing schedules in Part I and at MTD (or recommended dose) in Part II.
Study NCT01878617 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Craniospinal Irradiation with boost to the primary tumor site
Description: All participants will undergo craniospinal irradiation (CSI) with boost to the primary tumor site. The dose given is based on the molecular and risk group as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
Study NCT01878617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Route of Administration (ROA): Intravenously (IV)
Study NCT01878617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: ROA: IV
Study NCT01878617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: ROA: IV
Study NCT01489605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope Groove
Description: Patients will be intubated using the GlideScope Groove device. (Verathon)
Study NCT01489605 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control: Standard GlideScope
Description: Patients will be intubated using the standard GlideScope. (Verathon)
Study NCT03025776 — intervention group
Intervention type: BEHAVIORAL
Intervention: Reaching
Description: sitting reaching under various task conditions (size, speed, location)
Study NCT03025776 — intervention group
Intervention type: BEHAVIORAL
Intervention: Kinematic collection while reaching
Description: sitting reaching under various task conditions (size, speed, location), told how many \& which hand to use, kinematic data collected
Study NCT01952691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinesiotaping
Description: correction method was used to align hallux.
Study NCT02509260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena wound management system
Description: Patients will have the Prevena wound management system applied post-operatively.
Study NCT02509260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard wound dressings
Description: Control patients with standard wound dressings will have gauze and tape dressings applied
Study NCT00107016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001, Letrozole 2.5mg
Study NCT00107016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg
Study NCT01000116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin glue
Description: Tissucol 2 ml
Study NCT01000116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tacks
Description: Protacks
Study NCT01878617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: ROA: Orally (PO)
Study NCT01878617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: ROA: IV
Study NCT01878617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: ROA: IV
Study NCT01878617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Study NCT01723774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Study NCT01878617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Remediation
Study NCT01518179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Made-to-Measure Compression Gloves
Description: Made-to-Measure Compression Gloves in addition to routine follow up and treatment.
Study NCT01518179 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine follow up and treatment
Description: Control
Study NCT04421001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-port use
Description: patient will use I-port device fo 2 months
Study NCT04421001 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-port use
Description: patient will use I-port device fo 2 months
Study NCT03660449 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated conformal radiation combined With S-1
Description: All patients will receive two cycles of S-1 (40mg/㎡, BID, po) on D1-14, D22-35, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.
Study NCT01755403 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Benznidazole
Study NCT00002759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study NCT00002759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT05432362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aronia Juice
Description: The intervention is based an the additional consumption of 200 ml natural juice a day for a period of six weeks. The participants are asked to drink the natural and commercially available juice in addition to their regular diet. Further, they are asked not to change their diets and lifestyle behaviour during the intervention.
Study NCT00002759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenobarbital
Study NCT04279587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Residential camp
Description: Intensive education at a residential camp.
Study NCT02262663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Study NCT05432362 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A beverage is prepared according to a known recipe. It contains macro- and micronutrients in comparable amounts like the aronia juice. It is completely polyphenol free.
Study NCT03989284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based depression interventions
Description: We conducted three types of community-based depression interventions such as peer counseling, social engagement, and combination.
Study NCT00229151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation and sleep phase advancement
Description: Total sleep deprivation from 0800 to 1700 next day, and three day sleep phase advancement following sleep deprivation.
Study NCT00229151 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual treatment
Description: Treatment as usual in the psychiatric ward. Patients in this group will be offered treatment with sleep deprivation and sleep phase advancement after five weeks if they still meet inclusion criteria
Study NCT04576624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: A combined approach of a lifestyle structuring intervention to improve the general health and quality of life of persons with cognitive impairments. The investigators propose to combine a multi-modal cognitive intervention and lifestyle redesign approach to improve the cognitive health of older persons with cognitive impairments.
Study NCT01903590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVT surgery TOT surgery
Study NCT04576624 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: social activity
Description: 24 social gathering events
Study NCT02715973 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement
Description: Energy dense supplement appox. 2 kcal/mL, prepared from locally available, affordable, socially acceptable food items - milk, sugar, edible coconut oil, egg and custard powder as base) in addition to standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age.
Study NCT02715973 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nutritional Treatment
Description: Standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age
Study NCT03346044 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carpentier-Edwards SAV bioprostheses
Description: Performance of these bioprostheses
Study NCT03346044 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Mosaic bioprostheses
Study NCT04524169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin Alpha1
Description: Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.
Study NCT01903590 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT surgery TOT surgery
Study NCT02939079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Produced by Osveh ® Pharm Company in Iran
Study NCT02939079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod
Description: Produced by Osveh ® Pharm Company in Iran
Study NCT02939079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: produced by Zahravi ® Pharm Company in Iran
Study NCT02939079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Fish Oil)
Description: placebo capsules to mimic Fish Oil 1 g capsules
Study NCT01889524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mesh nebulizer
Description: VMN (NIVO, Respironics®, Murrysville, Pennsylvania, USA) with an MMAD of 3.0 µm was placed in the elbow adapter at the mask. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL.